Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Intercept Pharmaceuticals, Inc. - Common Stock (NQ:ICPT)

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Nov 7, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Intercept Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Ensysce Biosciences (NASDAQ:ENSC) stock increased by 74.49% to $5.2 during Thursday's pre-market session. The market value of their outstanding shares is at $... 
Via Benzinga
Intercept Posts Long-Term Data For Obeticholic Acid In Chronic Liver Disease Patients
Intercept Pharmaceuticals Inc (NASDAQ: ICPT) has announced results from a new analysis examining obeticholic acid's (OCA) potential to improve transplant-free... 
Via Benzinga
86 Biggest Movers From Yesterday
Gainers FAT Brands Inc. (NASDAQ: FATBB) shares gained 99.2% to settle at $15.44. FAT Brands recently announced plans to acquire Fazoli’s Restaurant Chain for $130 million.... 
Via Benzinga
Intercept Pharmaceuticals, inc (ICPT) Q3 2021 Earnings Call Transcript
ICPT earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Intercept Reports Narrower Q3 Loss; Raises Ocaliva Annual Sales Guidance
Intercept Pharmaceuticals Inc (NASDAQ: ICPT) reported Q3 sales of $92.8 million, up 17% Y/Y, surpassing the consensus of $83.02 million. Ocaliva net sales comprised U.S... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Glaukos (NYSE:GKOS) stock increased by 25.55% to $56.58 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.6 billion... 
Via Benzinga
The Daily Biotech Pulse: Cerus Climbs On Earnings, Horizon CFO To Retire, Teva Prices Upsized Sustainability-Linked Senior Note Offering
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Horizon Announces Retirement Of CFO, Beat-and-raise Q3 Horizon Therapeutics... 
Via Benzinga
Topics Retirement
Exposures Pension
The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 17) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
Gainers Cara Therapeutics (NASDAQ:CARA) ... 
Via Benzinga
58 Biggest Movers From Friday
Gainers Regencell Bioscience Holdings Limited (NASDAQ: RGC) shares climbed 204.1% to close at $19.16 on Friday. Regencell Bioscience reported partial exercise of underwriter... 
Via Benzinga
38 Stocks Moving In Friday's Mid-Day Session
Gainers GeoVax Labs, Inc. (NASDAQ: GOVX) shares climbed 45.8% to $6.27 after the company presented data from ongoing studies of its preventive vaccine against COVID-19, showing... 
Via Benzinga
Exposures COVID-19
Benzinga's Top Ratings Upgrades, Downgrades For August 20, 2021
Upgrades For Investors Bancorp Inc (NASDAQ: 
Via Benzinga
Intercept Downgraded To Sell From Neutral At Goldman Sachs
Goldman Sachs analyst Salveen Richter downgraded Intercept Pharmaceuticals to Sell from Neutral with a price target of $10, down from $17, implying a 30% downside. 
Via Talk Markets
10 Biggest Price Target Changes For Friday
Raymond James boosted the price target on The Estée Lauder Companies Inc. (NYSE: 
Via Benzinga
Return on Capital Employed Overview: Intercept Pharmaceuticals
After pulling data from Benzinga Pro it seems like during Q2, Intercept Pharmaceuticals (NASDAQ:ICPT) earned $760.00 thousand, a 102.59% increase from the preceding quarter.... 
Via Benzinga
Intercept Pharmaceuticals, inc (ICPT) Q2 2021 Earnings Call Transcript
ICPT earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Intercept Pharmaceuticals: Q2 Earnings Insights
Shares of Intercept Pharmaceuticals (NASDAQ:ICPT) moved higher by 3.6% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share... 
Via Benzinga
The Daily Biotech Pulse: Merck's Disappointing Q2, Atreca Falls On Data, FDA Nod For Viatris, Nuvalent, Icosavax IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 28) AbbVie Inc. (NYSE: ABBV)... 
Via Benzinga
Exposures Product Safety
Earnings Outlook For Intercept Pharmaceuticals
Intercept Pharmaceuticals (NASDAQ:ICPT) unveils its next round of earnings this Thursday, July 29. Get prepared with Benzinga's ultimate preview for Intercept Pharmaceuticals's Q2... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Acutus Medical (NASDAQ:AFIB) sto... 
Via Benzinga
The Week Ahead In Biotech (July 25-31): Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More
Biotech stocks rebounded in the week ended July 23, thanks to the broader market strength. The sector also benefitted from the optimism that was set in motion by the solid start... 
Via Benzinga
Exposures Product Safety
Why Intercept Pharmaceuticals Stock Shed 19% of Its Value in the First Six Months of 2021
The biotech can't seem to catch a break. 
Via The Motley Fool
Exposures Product Safety
The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26) I-Mab (NASDAQ: IMAB)... 
Via Benzinga
Exposures COVID-19
FDA Restricts Use Of Intercept's Ocaliva In Liver Disease with Advanced Cirrhosis Citing Risk Of Serious Liver Injury
The FDA has issued a statement restricting the use of Intercept Pharmaceuticals Inc’s (NASDAQ: ICPT) Ocaliva (obeticholic acid) in primary biliary... 
Via Benzinga
Exposures Product Safety
Stocks That Hit 52-Week Lows On Wednesday
Wednesday morning, 20 companies set new 52-week lows. Interesting Facts: The largest company in terms of market cap to set a new 52-week low was Ionis... 
Via Benzinga
The Daily Biotech Pulse: Nabriva Jumps On Data, Larimar Wilts After Study Put On Hold, Travere To Delay Regulatory Filing
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 25) ESSA Pharma Inc. (NASDAQ:... 
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Tuesday's morning session saw 16 companies set new 52-week lows. Noteworthy Points: The largest company in terms of market cap to set a new 52-week low was... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 25, 2021
Upgrades For Appian Corp (NASDAQ:APPN), Macquarie upgraded the previous rating of Underperform to Neutral. For the first quarter, Appian had an EPS of $0.06, compared to... 
Via Benzinga
The Daily Biotech Pulse: Pfizer In Vaccine Supply Talks With India, Provention In Focus Ahead Of Briefing Doc, NeuroRx To List Via SPAC Deal
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 24) Bristol-Myers Squibb Company... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.